

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number  
**WO 01/12803 A2**

(51) International Patent Classification<sup>7</sup>: C12N 15/11

(21) International Application Number: PCT/US00/22086

(22) International Filing Date: 11 August 2000 (11.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/149,313 17 August 1999 (17.08.1999) US

(71) Applicant (for all designated States except US): BETH ISRAEL DEACONESS MEDICAL CENTER, INC. [US/US]; 1 Deaconess Road, Boston, MA 02215 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): INOUE, Roger, T. [US/US]; 23 Roberts Road, Wellesley, MA 02481 (US). TORRES-VIERA, Carlos [VE/VE]; Calle Andrea de Ledesma, Qta La Torrera, Urb Sorocaima, Caracas,

Venezuela (VE). MOELLERING, Robert [US/US]; 49 Longfellow Road, Wellesley Hills, MA 02481-5220 (US). GOLD, Howard [US/US]; Apartment 610, 135 Pleasant Street, Brookline, MA 02446-3489 (US). ELIOPOULOS, George, M. [US/US]; 5 Laurel Circle, Needham, MA 02494 (US).

(74) Agent: PLUMER, Elizabeth, R.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).

(81) Designated States (national): CA, JP, US.

(84) Designated States (regional): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).


**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/12803 A2

(54) Title: METHODS AND COMPOSITIONS FOR RESTORING ANTIBIOTIC SUSCEPTIBILITY IN GLYCOPEPTIDE-RESISTANT *ENTEROCOCCUS*



(57) Abstract: Methods and compositions for reducing vancomycin resistance in a vancomycin resistant organism is provided. The methods involve delivering to the organism an isolated nucleic acid molecule that hybridizes to a target vancomycin gene and/or that serves as a *vanR*-responsive promoter decoy.